Regenxbio (RGNX) Cash from Investing Activities (2015 - 2025)

Regenxbio's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $37.5 million for Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 6.79% year-over-year to $37.5 million in Q4 2025; TTM through Dec 2025 was -$15.9 million, a 115.34% decrease from a year earlier, with the FY2025 full-year figure at -$15.9 million, down 115.34% from the prior year.
• Cash from Investing Activities eased to $37.5 million in Q4 2025 per RGNX's latest filing, from $42.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $63.1 million in Q1 2023 and bottomed at -$216.4 million in Q4 2021.
• The 5-year median for Cash from Investing Activities is $30.3 million (2022), against an average of -$7.0 million.
• Across the five-year window, Cash from Investing Activities jumped 5208.05% in 2023 and plunged 52301.49% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$216.4 million in 2021, then surged by 112.34% to $26.7 million in 2022, then grew by 27.24% to $34.0 million in 2023, then gained by 18.54% to $40.3 million in 2024, then fell by 6.79% to $37.5 million in 2025.
• Per Business Quant, the three latest RGNX Cash from Investing Activities figures stand at $37.5 million (Q4 2025), $42.3 million (Q3 2025), and -$140.4 million (Q2 2025).